Cancer Biology 2022
Last updated
We are pleased to present this special collection of articles recently published in LSA highlighting some of the latest advances in cancer biology. Articles featured in the collection were published within the past 12 months and include original findings on metastasis, genomics and mechanisms influencing cancer progression. We hope you enjoy reading this collection, and we invite you to follow LSA on Twitter (@LSAjournal). Learn more about submitting your research at https://www.life-science-alliance.org.
The tumor suppressor protein p53 inhibits ferroptosis by reducing the consumption of glutathione in nucleotide biosynthesis.
The retinoblastoma protein regulates mutagenic potential via control of UV-induced DNA lesion acquisition, thus revealing novel mechanisms that contribute to its tumor suppressor capabilities.
Necrotic debris and STING affect tumor cell growth by altering cholesterol homeostasis in opposing manner, revealing that modulation of cellular cholesterol load may help control tumor growth.
Tumor axonogenesis is an emerging hallmark of cancer and TGF-beta is a well-known cytokine involved in the control of cancer progression. In this study we identify a novel function for the TGF-beta signaling in cancer aggressivity by promoting cancer axonogenesis.
The cancer cells secrete VEGF, which induces vascular leakage and metastasis. Inhibition of VEGFR2 trafficking to the cell surface prevents receiving VEGF, vascular leakage, and cancer metastasis.
Expression dynamics of basement membrane-like extracellular matrix and fibronectin regulate transitions between solid (moruloid) and cavitational (blastuloid) phenotypes of ovarian cancer spheroids.
Single-cell RNA-Seq unravels heterogeneity and compartmentalization of both hepatitis B virus and cancer identifying new candidate pathways for viral hepatocarcinogenesis.
This work identifies the use of exosomes to specifically deliver CRISPR/Cas9 to target oncogenic KrasG12D mutation in pancreatic cancer as a nonviral therapeutic strategy.
Recurrent regulatory mutations affecting transcription factor binding sites in 2,500 cancer samples.
A single, neonatal UVB exposure drives greater UV-signature production in Braf- than Nras-mutant murine melanomas.
